Friday, December 4, 2020
banner
Home /  Front  /  MoPH inks pact with 2nd pharma firm to procure COVID-19 vaccine

MoPH inks pact with 2nd pharma firm to procure COVID-19 vaccine

MoPH inks pact with 2nd pharma firm to procure COVID-19 vaccine

Tribune News Network
Doha
The Ministry of Public Health (MoPH) has signed an agreement with a second pharmaceutical company to procure a COVID-19 vaccine as soon as it is approved and released for global use.
Dr Abdullatif Al Khal, Chair of the National Health Strategic Group on COVID-19, said the new agreement is with Moderna, a Massachusetts-based biotech company.
Dr Al Khal, who is also the head of Infectious Diseases at Hamad Medical Corporation, said, “Moderna has been working since the early days of the pandemic on the development and testing of a COVID-19 vaccine. Preliminary findings from Moderna’s phase 1 and 2 clinical trials have shown that healthy adults produced coronavirus neutralising antibodies and an immune reaction from T-cells. While further testing is ongoing on thousands of volunteers, these initial findings are encouraging and demonstrate that clear progress is being made in the search for a safe and effective vaccine.”
Moderna’s vaccine testing process follows the very high safety and quality standard typically applied for vaccine development. The testing process has involved more than 30,000 participants in the US.
According to the company, they are on track to supply around 500 million doses of the vaccine across the world from early 2021.
“The signing of the agreement with Moderna is a significant step forward in our country’s efforts to procure a safe and effective COVID-19 vaccine for the people of Qatar and comes following the announcement of our first agreement with a leading pharmaceutical company earlier this month,” said Dr Al Khal.
“We continue to work with several leading pharmaceutical companies around the world who are in the process of developing potential vaccines for COVID-19. Our aim is to ensure that we have access to the vaccines as soon as they demonstrate safety and efficacy and after they are approved by the appropriate international regulatory authorities,” Dr Al Khal said.
“While there is a chance that not all of these potential vaccines will prove successful, negotiating early and securing a number of agreements enhances our chances of getting sufficient quantities of the vaccine early on at a time where there will be a huge global demand for approved COVID-19 vaccines,” added Dr Al Khal.

Pages